MDD

Healis selected to present at key biotechnology and neuroscience investor conferences in Amsterdam, New York, and San Diego

Retrieved on: 
Monday, February 12, 2024
Neuroscience, Neuropsychiatry, BIO, Conference, CKD, Therapy, CNS, Patient, Major depressive disorder, MDD, Partnership, Pharmaceutical industry

NEWPORT BEACH, Calif., Feb. 12, 2024 (GLOBE NEWSWIRE) -- Healis Therapeutics is pleased to announce it has been competitively selected to present at several key investor conferences.

Key Points: 
  • NEWPORT BEACH, Calif., Feb. 12, 2024 (GLOBE NEWSWIRE) -- Healis Therapeutics is pleased to announce it has been competitively selected to present at several key investor conferences.
  • “It is an honor to return to my home country, the Netherlands, a pioneer in neuroscience, to present Healis Therapeutics, the leading biotech company in neuromodulation,” said Sebastian De Beurs, Co-Founder of Healis.
  • Healis will also be present at the BIO CEO & Investor Conference held in New York, NY on February 26-27, and at the Global Life Science Partnering & Investor Conference in San Diego, CA on February 28-29.
  • “We are excited to continue our dialogue with the world’s leading neuroscience investors and stakeholders” said Dr. Eric Finzi, who Co-Founded Healis Therapeutics.

Global Anxiety Disorders And Depression Treatment Market Analysis & Forecast 2024-2034: Market By Drug Class; By Indication; By Distribution Channel; and By Region - ResearchAndMarkets.com

Retrieved on: 
Thursday, February 8, 2024
Pharmaceutical, Health, Mental Health, Internet, Anxiety, DSM-IV codes, SAD, MDD, Research, PureTech Health, USD, Pharmacy, Social anxiety disorder, Prevalence, Patient, Distribution, GAD, PH94B, Ulotaront, FDA, Disorder, Tic disorder, PPD, Market, Depression, AbbVie, Zuranolone, MOA, Food, Commercialization, Therapy, TAAR1, Major depressive disorder, Sunovion, ADAA, Postpartum depression, NDA, Biogen, Conference, Pharmaceutical industry

The "Global Anxiety Disorders And Depression Treatment Market Analysis & Forecast 2024-2034: Market By Drug Class; By Indication; By Distribution Channel; and By Region" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Anxiety Disorders And Depression Treatment Market Analysis & Forecast 2024-2034: Market By Drug Class; By Indication; By Distribution Channel; and By Region" report has been added to ResearchAndMarkets.com's offering.
  • The global anxiety disorders and depression treatment market size was estimated to be USD 21.56 billion in 2023 and is expected to reach at USD 41.83 billion by 2034 with a CAGR of 6.21% during the forecast period 2024-2034.
  • Rising research & development activities for the development of innovative drugs for the treatment of anxiety & depression disorders is predicted to boost the market growth during the forecast period.
  • This application pertains to the use of cariprazine as an add-on treatment for individuals with major depressive disorder (MDD) who are already undergoing antidepressant therapy.

EQS-News: Marinomed Biotech AG with important progress for Carragelose in 2024

Retrieved on: 
Wednesday, February 7, 2024
Internal medicine, Certification, Telecanthus, MDR, Trial of the century, Nose, Patient, Procter & Gamble, FDA, Canadian International Council, OTC, Allergic rhinitis, MDD, Medical device regulation, Medical device, Allergy

Marinomed has received patents covering the decongestant Carragelose/Sorbitol combination in Singapore, South Korea, and Brazil

Key Points: 
  • Marinomed has received patents covering the decongestant Carragelose/Sorbitol combination in Singapore, South Korea, and Brazil
    Korneuburg, Austria, 07 February 2024 – Marinomed Biotech AG (VSE:MARI) has enrolled the first patient in a clinical study to investigate the lubricating properties of Carragelose eye drops in patients diagnosed with mild to moderate dry eye disease.
  • Carragelose eye drops are planned to launch in Austria in 2024.
  • Next to the eye drops, also the launch of the allergen-blocking Carragelose nasal spray is planned for 2024.
  • We are happy that the Carragelose business is constantly making progress and we continue to maximize the value of this asset”, Andreas Grassauer, Marinomed’s CEO, mentions.

InspireMD Receives CE Mark Recertification Under EU’s New Medical Device Regulation (MDR) Regulatory Framework

Retrieved on: 
Wednesday, January 31, 2024
EPS, Standard of care, MDR, PMA, TEL, FDA, Marketing, MDD, Medical device regulation, CE marking, NSPR, Stroke, European, Medical device

TEL AVIV, Israel and MIAMI, Jan. 31, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Carotid Stent System (EPS) for the prevention of stroke, today announced that it has received CE Mark recertification under the European Union’s new Medical Device Regulation (MDR) regulatory framework.

Key Points: 
  • TEL AVIV, Israel and MIAMI, Jan. 31, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Carotid Stent System (EPS) for the prevention of stroke, today announced that it has received CE Mark recertification under the European Union’s new Medical Device Regulation (MDR) regulatory framework.
  • MDR replaced the previous MDD framework, which had governed the approval and marketing of medical devices in the EU until May of 2021.
  • Marvin Slosman, chief executive officer of InspireMD, stated, “The transition from MDD to MDR has been challenging and has required us, and others in the medical device industry, to be comprehensive and persistent in our approach to addressing changes in requirements, timelines, and priorities during this process.
  • We continue to aggressively work toward multiple value creating milestones, including the potential U.S. approval of the CGuard Prime EPS stent system in the first half of 2025,” Mr. Slosman concluded.

ANeuroTech publishes Phase IIIa data for ANT-01, an adjunctive anti-depression drug, in Personalized Medicine in Psychiatry

Retrieved on: 
Wednesday, January 31, 2024
Com, Psychosis, Dopamine, Patient, Serotonin, Depression, MDD, Mental health, Phase, Anhedonia, Citalopram, Patent, Prodrug, Pleasure, Pipamperone, Pharmaceutical industry

ANeuroTech publishes Phase IIIa data for ANT-01, an adjunctive anti-depression drug, in Personalized Medicine in Psychiatry

Key Points: 
  • ANeuroTech publishes Phase IIIa data for ANT-01, an adjunctive anti-depression drug, in Personalized Medicine in Psychiatry
    Alken, Belgium – 31 January 2024: ANeuroTech, a leader in the development of innovative mental health treatments with minimal or no side effects, today announced the publication of Phase IIIa data for ANT-01, its adjunctive anti-depression drug, in the journal of Personalized Medicine in Psychiatry.
  • The Company also filed a Composition of Matter (CoM) patent for the long-acting effects of ANT-01.
  • The paper was co-authored by Erik Buntinx, Lars Bastiaanse, Alan S Schatzberg, Charles B Nemeroff and Philip D Harvey.
  • At ANeuroTech, we are working to bring effective treatments, with minimal or no side-effects, to patients who suffer with depression.

ClearPoint Neuro Announces First EU MDR Certification Success and Approval to Ship Product to Europe

Retrieved on: 
Monday, January 22, 2024
MDR, Data collection, Spine, Medical device, Quality, Risk management, MDD, Brain, Certification

Additionally, the Company received updated certification from its Notified Body allowing for shipment of products manufactured at its new Carlsbad, California facility to Europe.

Key Points: 
  • Additionally, the Company received updated certification from its Notified Body allowing for shipment of products manufactured at its new Carlsbad, California facility to Europe.
  • European Medical Device Regulation 2017/745 (EU MDR), the new medical device regulation applicable in Europe, replaces the previous Medical Device Directive 93/42/EEC (MDD) regulation.
  • With the introduction of EU MDR, the EU is placing greater emphasis on safety measures, risk management, post-market surveillance, and data collection of medical devices for companies who wish to obtain European market access.
  • “Our team has risen to this challenge, especially given the importance of the EU to our pharmaceutical partners.”

Neumora Therapeutics Appoints Kaya Pai Panandiker as Chief Commercial Officer

Retrieved on: 
Monday, January 22, 2024
Schizophrenia, Patient, Therapy, Public policy, University of Chicago, University, Neuropsychiatry, DSM-IV codes, University of Wisconsin–Madison, Vortioxetine, Brain, MDD

WATERTOWN, Mass., Jan. 22, 2024 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced the appointment of Kaya Pai Panandiker as chief commercial officer and a member of Neumora’s executive team, reporting to Henry Gosebruch, president and chief executive officer.

Key Points: 
  • WATERTOWN, Mass., Jan. 22, 2024 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced the appointment of Kaya Pai Panandiker as chief commercial officer and a member of Neumora’s executive team, reporting to Henry Gosebruch, president and chief executive officer.
  • Ms. Pai Panandiker brings extensive commercial strategy and execution expertise to Neumora, having led the launches of multiple neuropsychiatry products throughout her career.
  • Prior to joining Neumora, Ms. Pai Panandiker served as head of commercial at Cerevel Therapeutics and general manager, neuroscience at Lundbeck US.
  • “It is an incredibly exciting time to join Neumora as we progress pivotal studies in MDD and advance a deep pipeline in schizophrenia, Alzheimer’s, Parkinson’s and other disease areas with significant unmet medical need,” said Kaya Pai Panandiker, chief commercial officer, Neumora.

GH Research Announces Grant of European Patent Covering all Mebufotenin (5-MeO-DMT) and Mebufotenin Salt Products For Use in the Treatment of Major Depressive Disorder and Treatment-Resistant Depression

Retrieved on: 
Thursday, January 18, 2024
DSM-IV codes, European Patent Convention, Patient, EPO, IP, Psychiatry, Communication, TRD, MDD, Patent, Research, GHRS, Pharmaceutical industry

It is therefore expected to effectively fortify the company’s position at the forefront of novel rapid-acting antidepressant treatments.

Key Points: 
  • It is therefore expected to effectively fortify the company’s position at the forefront of novel rapid-acting antidepressant treatments.
  • Theis Terwey, CEO and Co-founder of GH Research said: “We are committed to providing highly effective new therapies to patients in mental health care who are underserved by existing treatments.
  • Having a strong IP portfolio helps us with this mission, and it is satisfying to have the EPO endorse the strength of our IP.
  • We feel well placed to progress the rest of our patent portfolio through the examination process in Europe, the US and beyond, and are looking forward to exploring additional opportunities with mebufotenin through continuous research and development.”

Motif Neurotech Raises $18.75 Million in Series A Financing to Advance Implantable Device for Treatment-Resistant Depression

Retrieved on: 
Wednesday, January 24, 2024
Technology, Mobile, Wireless, Research, Medical Devices, Neurology, Biotechnology, Other Health, Health, Science, Patient, Multimedia, Mental health, Quality of life, DOT, TRD, DSM-IV codes, Capital, Brain, Motif, Depression, Trial of the century, MDD, Medical device

View the full release here: https://www.businesswire.com/news/home/20240124154216/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240124154216/en/
    To-scale rendering of the prototype Motif DOT microstimulator used in their first-in-human and large animal studies.
  • The initial indication Motif is pursuing for the device is treatment-resistant depression (TRD), a form of major depressive disorder (MDD) that is resistant to anti-depressant medications.
  • “Minimally-invasive bioelectronics are the future of mental health treatment,” said Jacob Robinson, CEO & Founder, Motif Neurotech.
  • The DOT microstimulator is a wireless, battery-free device designed to be implanted in a 20-minute outpatient procedure with the capability for at-home therapy.

Gate Neurosciences Announces Clinical Collaboration with Beacon Biosignals to Advance Precision EEG Biomarkers in Major Depressive Disorder

Retrieved on: 
Wednesday, January 24, 2024
Research, Mental Health, Medical Devices, Neurology, Clinical Trials, Biometrics, Biotechnology, Pharmaceutical, Health, Science, Patient, Sleep, EEG, Food and Drug Administration, NMDA, Mental health, Algorithm, NMDAR, Neuropsychiatry, Depression, Food, Neuroscience, Cognition, DSM-IV codes, FDA, Biomarker, Myenteric plexus, Gate, Clinical trial, Diagnosis, Medicine, Beacon, MDD, Medical imaging

Gate Neurosciences , a clinical-stage biotechnology company using precision medicine approaches to develop next-generation neuroscience therapies, today announced a strategic collaboration with Beacon Biosignals to further advance the use of electroencephalogram (EEG) biomarkers across the company’s clinical pipeline in neuropsychiatry and cognition.

Key Points: 
  • Gate Neurosciences , a clinical-stage biotechnology company using precision medicine approaches to develop next-generation neuroscience therapies, today announced a strategic collaboration with Beacon Biosignals to further advance the use of electroencephalogram (EEG) biomarkers across the company’s clinical pipeline in neuropsychiatry and cognition.
  • Zelquistinel is a rapid-acting, once-weekly oral NMDA receptor positive modulator in development for treating major depressive disorder (MDD).
  • “The Gate team is excited to partner with Beacon in pioneering a new era of precision psychiatry with innovative biomarker insights, approaches, and technology,” commented Mike McCully, CEO of Gate Neurosciences.
  • The Dreem™ 3S data flows into Beacon Biosignals' analytics platform to provide validated neurophysiological endpoints for clinical trials.